Show simple item record

dc.contributor.authorChandrasekhar, J.
dc.contributor.authorBaber, U.
dc.contributor.authorSartori, S.
dc.contributor.authorAquino, M. B.
dc.contributor.authorHájek, P.
dc.contributor.authorAtzev, B.
dc.contributor.authorHudec, M.
dc.contributor.authorKiam Ong, T.
dc.contributor.authorMates, M.
dc.contributor.authorBorisov, B.
dc.contributor.authorWarda, H. M.
dc.contributor.authorden Heijer, P.
dc.contributor.authorWojcik, J.
dc.contributor.authorIñiguez Romo, Andres 
dc.contributor.authorCoufal, Z.
dc.contributor.authorKhashaba, A.
dc.contributor.authorMunawar, M.
dc.contributor.authorGerber, R. T.
dc.contributor.authorYan, B. P.
dc.contributor.authorTejedor, P.
dc.contributor.authorKala, P.
dc.contributor.authorBang Liew, H.
dc.contributor.authorLee, M.
dc.contributor.authorKalkman, D. N.
dc.contributor.authorDangas, G. D.
dc.contributor.authorde Winter, R. J.
dc.contributor.authorColombo, A.
dc.contributor.authorMehran, R.
dc.date.accessioned2022-05-19T08:33:31Z
dc.date.available2022-05-19T08:33:31Z
dc.date.issued2020
dc.identifier.issn2352-9067
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32953969es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16741
dc.description.abstractBackground: The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization. Objective: We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score. Methods: MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score </= 3 and intermediate-to-high (IHBR) for score > 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-driven target lesion revascularization (TLR). Bleeding was adjudicated using the Bleeding Academic Research Consortium (BARC) definition. Dual antiplatelet therapy (DAPT) cessation was independently adjudicated. Results: The study included 56% (n = 1270) LBR and 44% (n = 1009) IHBR patients. Incidence of 1-year TLF was higher in IHBR patients (4.1% vs. 2.6%, p = 0.047) driven by cardiac death (1.7% vs. 0.7%, p = 0.029) with similar rates of MI (1.8% vs. 1.1%, p = 0.17), TLR (1.5% vs. 1.6%, p = 0.89) and definite/ probable stent thrombosis (1.2% vs. 0.6%, p = 0.16). Incidence of 1-year major BARC 3 or 5 bleeding was significantly higher in IHBR patients (2.3% vs. 0.9%, p = 0.0094), as was the incidence of DAPT cessation (29.3% vs. 22.8%, p < 0.01), driven by physician-guided discontinuation. Conclusions: Patients with intermediate-to-high PARIS bleeding risk in the MASCOT registry experienced greater incidence of 1-year TLF, major bleeding and DAPT cessation than LBR patients, without significant differences in stent thrombosis.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registryen
dc.typeJournal Articlees
dc.authorsophosChandrasekhar, J.;Baber, U.;Sartori, S.;Aquino, M. B.;Hájek, P.;Atzev, B.;Hudec, M.;Kiam Ong, T.;Mates, M.;Borisov, B.;Warda, H. M.;den Heijer, P.;Wojcik, J.;Iniguez, A.;Coufal, Z.;Khashaba, A.;Munawar, M.;Gerber, R. T.;Yan, B. P.;Tejedor, P.;Kala, P.;Bang Liew, H.;Lee, M.;Kalkman, D. N.;Dangas, G. D.;de Winter, R. J.;Colombo, A.;Mehran, R.
dc.identifier.doi10.1016/j.ijcha.2020.100605
dc.identifier.pmid32953969
dc.identifier.sophos40494
dc.journal.titleIJC HEART & VASCULATUREes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Cardioloxíaes
dc.page.initial100605es
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUVIes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number31.es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International